The programs will be implemented jointly with leading Russian pharmaceutical companies and research centers.

Sirius University of Science and Technology has introduced two new master’s programs designed to train specialists for biotechnology companies, as well as the pharmaceutical and medical industries, the university’s press service told TASS.

“They have been developed and will be implemented in partnership with leading Russian pharmaceutical companies and research centers. The programs are tuition-free and will last two years. Applications open on June 20, 2026,” the press service said.

The master’s programs were presented at the Sirius.Biotech drug development summit. The new tracks are Immunobiotechnology and Advanced Materials and Chemical Technologies in Medicine.

The Immunobiotechnology master’s program is aimed at training specialists capable of participating in all stages of modern biotechnological drug development—from designing biotechnological processes to scaling them up, transferring technologies, and implementing quality control methods at industrial production sites. Students will study producer cultivation technologies, isolation and purification of biopharmaceutical products, and the production of vaccines and gene therapy drugs in line with current regulatory requirements.

The second new program, Advanced Materials and Chemical Technologies in Medicine, combines medicinal chemistry, materials science, and biomedicine. It is designed to train specialists who will develop innovative small molecules, targeted drug delivery systems, biomaterials for tissue engineering, regenerative medicine, and diagnostics.

“The main barrier to the development of advanced pharmaceutical and medical technologies in our country is the shortage of highly skilled personnel. Our task is to fill this gap with talented researchers. The master’s programs have been developed in close cooperation with leading domestic industry partners, research centers, and biopharmaceutical companies such as R-Pharm, AstraZeneca, and others. This brings the educational process as close as possible to the real challenges of modern drug development. As a result, we can train young specialists who will be ready for the most serious challenges from the very start,” said Roman Ivanov, Director of the Research Center for Translational Medicine and Chairman of the Academic Council of Sirius University of Science and Technology.

About the Summit

The Sirius.Biotech 2026 drug development summit is taking place at Sirius University of Science and Technology on May 20–22. Participants, including drug developers and manufacturers, are discussing current research in the field and the state of the industry.

Source: TASS, May 22, 2026.